Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Dabigatran Etexilate with Pantoprazole in Healthy Volunteers
NCT02170740Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 1999
- Primary completion
- Jan 2000
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Urinary excretion of total BIBR 953 ZW at Day 3, Peak plasma concentration at steady state of BIBR 953 ZW at Day 3 and 2 more. Started Nov 1999; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02170740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02170740.